Medical Devices · us
Giving Donor Lungs a “Second Test” Outside the Body: TorEx Perfusion System Receives FDA Approval
The system allows donor lungs originally deemed unsuitable for transplantation to undergo continuous perfusion for up to six hours in an environment near body temperature, giving medical teams an opportunity to reassess their function. It provides an additional opportunity for evaluation, not a guarantee that every organ can be transplanted.
A longstanding challenge in lung transplantation is that many donor lungs are discarded after initial assessment because of concerns about their function. The US Food and Drug Administration (FDA) has now approved the TorEx Lung Perfusion System, allowing lungs originally deemed unsuitable for transplantation to remain functioning outside the body and undergo further testing, potentially expanding the pool of organs available to people awaiting transplants.
FDA records show that TorEx received premarket approval on July 15, 2026, for use in adult lung transplantation. The system provides donor lungs with continuous mechanical perfusion under normothermic conditions—that is, at a temperature close to normal human physiological temperature—for up to six hours. During this period, transplant teams can reassess the lungs’ function outside the body instead of relying solely on one-time evaluations before and after retrieval.
The platform consists of a mobile cart equipped with built-in software, a single-use sterile organ chamber and cannulas, and a dedicated cell-free perfusion solution. Its central concept is not simply to extend preservation time, but to keep the lungs ventilated and perfused in a controlled environment, enabling physicians to obtain information that more closely reflects their actual operating state before determining whether the organs meet transplantation criteria.
Developer Traferox Technologies said the company and its partner transplant centers have completed more than 400 TorEx procedures to date, with about 67% of the marginal donor lungs evaluated ultimately selected for transplantation. However, these figures come from a company press release and are not sufficient on their own to demonstrate that the system can achieve the same utilization rate or long-term clinical outcomes across different hospitals. Whether an individual organ is suitable for transplantation still depends on the recipient’s condition, the team’s judgment, and the complete clinical data.
TorEx originated from ex vivo lung perfusion research at Canada’s University Health Network and the University of Toronto. Traferox is preparing for commercial launch in the United States, but the scope of the FDA approval clearly limits the system’s role: it provides an assessment of donor-lung quality, while the final transplantation decision remains with the surgeon performing the transplant. Improvements after perfusion cannot be regarded directly as a guarantee that the organ can be transplanted safely.
The FDA also requires continued post-approval follow-up and has linked the related study to clinical trial NCT05656404. Publicly available information shows that the study protocol was still pending when the page was most recently updated. The first six-month report is expected to be submitted in January 2027, with subsequent periodic reports continuing through 2030. These data will help clarify whether TorEx not only allows more lungs to pass reassessment, but can also maintain acceptable transplant outcomes and safety in broad clinical use.